Seres Therapeutics Stock In The News

MCRB Stock  USD 1.02  0.01  0.97%   
The tone or emotional content of news articles related to Seres Therapeutics can affect its prices. Positive news sentiment can lead to an increase in demand for Seres Therapeutics' stock, while negative news sentiment can lead to a decrease in demand. Our overall analysis of Seres Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Seres Therapeutics. The specific impact of Seres Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Seres Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Seres Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Seres Therapeutics Backtesting and Seres Therapeutics Hype Analysis.
For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide.

Seres Therapeutics Today Top News and Investor Outlook

Yahoo News
11 Oversold NASDAQ Stocks To Buy Right Now
https://finance.yahoo.com/news/11-oversold-nasdaq-stocks-buy-193220134.html
 Bullish
Yahoo News
11 Oversold Healthcare Stocks To Buy Right Now
https://finance.yahoo.com/news/11-oversold-healthcare-stocks-buy-121714179.html
 Bullish
Yahoo News
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
https://finance.yahoo.com/news/seres-therapeutics-reports-inducement-grants-120000103.html
 Bullish
Yahoo News
Halozyme Therapeutics (HALO) Surges 5.6%: Is This an Indication of Further Gains?
https://finance.yahoo.com/news/halozyme-therapeutics-halo-surges-5-090100581.html
 Bullish
Yahoo News
Seres Therapeutics Announces VOWSTâ„¢ Commercial Launch Update and US FDA Fast Track Designation for SER-155
https://finance.yahoo.com/news/seres-therapeutics-announces-vowst-commercial-120000832.html
 Bullish
Yahoo News
Seres Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
https://finance.yahoo.com/news/seres-therapeutics-participate-42nd-annual-210000751.html
 Neutral
Yahoo News
Seres Therapeutics Announces Presentatio...
https://finance.yahoo.com/news/seres-therapeutics-announces-presentation-preliminary-004600695.html
 Neutral
Yahoo News
Seres Therapeutics, Inc. (NASDAQ:MCRB) is a favorite amongst institutional investors who own 62%
https://finance.yahoo.com/news/seres-therapeutics-inc-nasdaq-mcrb-135441112.html
 Bullish
Yahoo News
Seres Therapeutics to Participate in the...
https://finance.yahoo.com/news/seres-therapeutics-participate-piper-sandler-141800097.html
 Neutral
Yahoo News
Thermo Fisher Scientific & Flagship Pion...
https://finance.yahoo.com/news/thermo-fisher-scientific-flagship-pioneering-130000507.html
 Bullish

Seres Therapeutics Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Seres and other traded companies coverage. We help investors stay connected with Seres headlines for the 11th of May 2024 to make an informed investment decision based on correlating the impacts of news items on Seres Stock performance. Please note that trading solely based on the Seres Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Seres Therapeutics' linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Seres Therapeutics investors visualize upcoming and past events in order to time the market based on Seres Therapeutics noise-free hype analysis.
Seres Therapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Seres earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Seres Therapeutics that are available to investors today. That information is available publicly through Seres media outlets and privately through word of mouth or via Seres internal channels. However, regardless of the origin, that massive amount of Seres data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Seres Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Seres Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Seres Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Seres Therapeutics alpha.

Seres Largest EPS Surprises

Earnings surprises can significantly impact Seres Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2020-03-02
2019-12-31-0.28-0.250.0310 
2021-03-02
2020-12-31-0.28-0.230.0517 
2015-11-10
2015-09-30-0.32-0.38-0.0618 
2024-05-08
2024-03-31-0.34-0.270.0720 
2023-03-07
2022-12-31-0.46-0.54-0.0817 
2022-03-01
2021-12-31-0.44-0.52-0.0818 
View All Earnings Estimates

Seres Therapeutics Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Seres Therapeutics Stock. The global stock market is bullish. About 63% of major world exchanges and indexes are currently up. See today's market update for more information.
seekingalpha News
9th of May 2024
Novo Nordisk, Flagship to develop next-generation obesity drugs
at seekingalpha.com 
sbwire news
8th of May 2024
MCRB Stock Earnings Seres Therapeutics Beats EPS for Q1 2024
at investorplace.com 
Yahoo News
6th of May 2024
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635
at finance.yahoo.com 
Google News at Macroaxis
3rd of May 2024
Seres Therapeutics investors will be pleased with their respectable 70 percent return over...
at news.google.com 
Google News at Macroaxis
5th of April 2024
Seres Therapeutics Stock Price Crosses Below 50-Day Moving Average of 0.98 - Defense World
at news.google.com 
businesswire News
28th of March 2024
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635
at businesswire.com 
Yahoo News
19th of March 2024
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635
at finance.yahoo.com 
seekingalpha News
5th of March 2024
Seres Therapeutics GAAP EPS of -0.89 beats by 0.10, revenue of 126.33M beats by 0.23M
at seekingalpha.com 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Seres Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Seres Therapeutics' short interest history, or implied volatility extrapolated from Seres Therapeutics options trading.
When determining whether Seres Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Seres Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Seres Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Seres Therapeutics Stock:
Check out Seres Therapeutics Backtesting and Seres Therapeutics Hype Analysis.
For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide.
You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.

Complementary Tools for Seres Stock analysis

When running Seres Therapeutics' price analysis, check to measure Seres Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Seres Therapeutics is operating at the current time. Most of Seres Therapeutics' value examination focuses on studying past and present price action to predict the probability of Seres Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Seres Therapeutics' price. Additionally, you may evaluate how the addition of Seres Therapeutics to your portfolios can decrease your overall portfolio volatility.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Is Seres Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Seres Therapeutics. If investors know Seres will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Seres Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.89)
Revenue Per Share
0.953
Quarterly Revenue Growth
(0.93)
Return On Assets
(0.16)
Return On Equity
(5.39)
The market value of Seres Therapeutics is measured differently than its book value, which is the value of Seres that is recorded on the company's balance sheet. Investors also form their own opinion of Seres Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Seres Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Seres Therapeutics' market value can be influenced by many factors that don't directly affect Seres Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Seres Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Seres Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Seres Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.